The tweet was deleted by the author.
But we saved everything 🙂.
Biomea Fusion announced results from its Phase 2 COVALENT-111 study, showing Icovamenib led to significant improvements in patients with insulin-deficient type 2 diabetes. The therapy yielded durable reductions in HbA1c at one year, following a 12-week treatment period.
Key findings included a roughly 24 percent increase in insulin secretion and enhanced beta-cell function. These results suggest Icovamenib may offer a novel therapeutic avenue for those who are insulin-deficient. Full coverage is available via Healio.
Biomea Fusion previously highlighted plans to present Icovamenib clinical data targeting diabetes innovation at ATTD 2006, according to an earlier announcement. The company continues to focus on beta cell restoration with Icovamenib, as outlined in a statement supporting the therapy’s promise. These efforts form part of Biomea Fusion’s ongoing strategy in diabetes research.